STUDresearch · Peptide
Tuftsin
Also known as
Thr-Lys-Pro-Arg · tuftsin tetrapeptide
Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Niche talk
Systemic
IV
Immune / antimicrobial
Endogenous immune-signaling tetrapeptide studied systemically by IV; no organ-specific capsule exposure or consumer injection pattern was established.
What people say
Tuftsin is the endogenous IgG-derived tetrapeptide Thr-Lys-Pro-Arg, studied for phagocyte-stimulating immune activity. It is not a Khavinson organ bioregulator, and results or experiences for Selank cannot be assigned to Tuftsin.
Doses people talk about
Research doses in advanced-cancer patients are not consumer instructions and do not validate a gray-market product. Milligrams, micrograms, IV route and any consumer route must remain separate.
How it may feel
No credible direct Tuftsin self-use chronology was found in the reviewed community material. The historical IV cancer study recorded leukocyte and disease outcomes, not a consumer felt experience.
Earlier consumer discussion~50–500 mcg; route and frequency not established
The earlier community range does not specify route, frequency or product identity; it cannot be treated as equivalent to the IV study regimens.
1986 Phase I escalation0.0025–0.98 mg/kg IV
Fifteen advanced-cancer patients received escalating IV amounts; the publication described leukocyte response and tolerability, not consumer use.
1986 Phase II regimen5 mg IV, 2–3 times weekly
Twenty-five advanced-cancer patients entered the repeated-dose phase; this is a historical research regimen, not a settled consumer schedule.
Half-life & effect duration
- Half-life in the body
- Half-lifeNo settled estimate
- Felt duration people report
- Felt durationNo direct consumer-use timeline reported
Cycles people discuss
The old profile preserves seasonal short-course lore, but no Tuftsin-specific consumer cycle was established. The historical human study used repeated IV visits, which is a research regimen rather than a retail cycle.
Timing
The general community notes consider side effects, training and sleep rather than an exact clock. They do not establish a Tuftsin-specific preferred hour or meal window.
Stacks
The retained notes describe generic multi-bioregulator stacking and the difficulty of attributing effects, not a documented Tuftsin-specific combination account.
Watch for
Unknowns: Long-term safety for gray-market preparations is often poorly characterized.
Tap a line for the full notes and source context.
Timing context & sources
Half-life in the body
No route-specific human parent Tuftsin half-life was established in the material reviewed.
The 1986 IV study reports dose and clinical response, not a concentration-time PK estimate. A recent in-vitro aminopeptidase-N model reports rapid unprotected degradation, but that is not human blood clearance.
No human PK sampling package was located; laboratory matrix, oral protection system and IV clinical exposure are different contexts.
- Initial clinical studies with Tuftsin (opens in a new tab)Full publication metadata and abstract reviewed. Phase I: 15 advanced-cancer patients, IV 0.0025–0.98 mg/kg, with minimum leukocytosis dose reported as 0.02 mg/kg. Phase II: 25 patients, 5 mg IV 2–3 times weekly; among 16 evaluable patients, 2 responses, 5 stable and 9 progressed.Small uncontrolled 1986 oncology study with disease and leukocyte outcomes; it does not report a human parent half-life or validate consumer routes or products.
- Oral peptide drug delivery: design of SEDDS providing a protective effect against intestinal membrane-bound enzymes (opens in a new tab)Full article reviewed. In the in-vitro aminopeptidase-N assay, unprotected Tuftsin at 1 mg/mL was completely degraded within 15 minutes, while the tested SEDDS retained more than 90% after four hours.In-vitro formulation-stability model, not human oral absorption, blood half-life, clinical efficacy or a consumer dose source.
Felt duration people report
No direct consumer onset or felt-duration window for Tuftsin was established.
The reviewed community page discussed Selank as a Tuftsin analogue but did not supply a direct Tuftsin self-use report. The human oncology study used clinical and leukocyte endpoints rather than a felt-duration endpoint.
Absence in this bounded review is not proof that no report exists; analogue reports and clinical course schedules cannot fill the missing clock.
- Selank discussion referencing Tuftsin as its native parent (opens in a new tab)Full visible post and discussion reviewed. Tuftsin appears as the native peptide from which Selank was designed; the page discusses Selank rather than a direct Tuftsin self-use course.Community educational post, not a direct Tuftsin experience, PK source or proof that Selank route, dose or effects transfer to Tuftsin.
- Initial clinical studies with Tuftsin (opens in a new tab)Full publication metadata and abstract reviewed. Phase I: 15 advanced-cancer patients, IV 0.0025–0.98 mg/kg, with minimum leukocytosis dose reported as 0.02 mg/kg. Phase II: 25 patients, 5 mg IV 2–3 times weekly; among 16 evaluable patients, 2 responses, 5 stable and 9 progressed.Small uncontrolled 1986 oncology study with disease and leukocyte outcomes; it does not report a human parent half-life or validate consumer routes or products.
Other context in this card
- Tuftsin (an Ig-associated tetrapeptide) triggers the immunogenic function of macrophages: implications for activation of programmed cells (opens in a new tab)PubMed record and abstract reviewed. It identifies Tuftsin as the IgG heavy-chain tetrapeptide Thr-Lys-Pro-Arg and describes stimulation of phagocytic-cell functions.Identity and immune-function research, not a route-specific human PK study, consumer experience source or modern efficacy trial.
What people say
- immunostimulatory tetrapeptide narrative: Community and regional literature frame benefits around immunostimulatory tetrapeptide function and “normalization” language. forum
- What is thinner: Large modern multi-center RCTs are often absent for the specific peptide brand story. forum
- Why it trends: Tuftsin is discussed mainly for immune-related goals in community and secondary sources. forum
- Consumer evidence boundary: The reviewed community discussion referred to Tuftsin mainly as Selank's native parent; it did not provide a direct Tuftsin self-use outcome. Selank anecdotes cannot be transferred to Tuftsin. forum
- Time course: Early days are often side-effect or placebo window; multi-week blocks are the real checkpoint. forum
Doses people talk about
- Earlier consumer discussion: ~50–500 mcg is reported without a defined route, frequency or product identity. Historical human research used defined IV milligram regimens; the contexts are not interchangeable. forumtrial
- Route: injection in lab/product talk; not a standard oral supplement dose. forum
- No single settled consumer daily dose. forum
- Framing: Immune tetrapeptide research; human charts sparse. forum
How it may feel
- Direct consumer clock: No credible direct Tuftsin self-use chronology was established in the community material reviewed. The old IV oncology study reported clinical and leukocyte outcomes, not a consumer felt-onset or oral GI/mood timeline. forumtrial
- Courses: Often 10–20 day courses repeated a few times per year in bioregulator culture. forum
- Day 1: Most people notice logistics (route, sting, GI) more than a “miracle” effect from Tuftsin. forum
- Days 2–7: Side-effect window for many agents; benefits, if any, are easy to mis-attribute. forum
- Weeks 1–2: First honest checkpoint in self-logs. forum
Cycles people discuss
- Course culture: Short on, long off, repeat seasonally is the common pattern. forum
- Common pattern: Many self-protocols use weeks-on / weeks-off rather than indefinite daily use — cost and caution drive this more than hard science. forum
- No magic cycle: There is rarely one universal “correct” on/off calendar across forums. forum
- Reassess: Stop and reassess if adverse effects appear; this is not medical care. forum
Timing
- Timing practicalities: People time doses around side effects, training, and sleep more than perfect PK. forum
- Human parent PK: Not established in the material reviewed. Rapid degradation by aminopeptidase N in an in-vitro intestinal-enzyme model is not a human bloodstream half-life, and peptide size alone cannot supply one. trial
- Published PK: Where human PK exists it should override forum half-life memes for Tuftsin. trial
More on what it is
- Evidence honesty: Much of the English-web discussion is secondary summaries and vendor literature; treat claims cautiously. forum
- Research posture: Educational summary of public discussion and literature themes only. forum
- How people talk about it: Forum volume is a popularity signal for Tuftsin, not proof it works for you. forum
- What it is: Tuftsin is the endogenous tetrapeptide Thr-Lys-Pro-Arg, derived from the Fc region of IgG and studied for phagocyte-stimulating immune activity. It is not a Khavinson organ bioregulator, and Selank being a synthetic Tuftsin analogue does not make Selank experience Tuftsin experience. trial
- Research only: Not approved advice for self-experimentation; legality and access vary by place. forum
Stacks
- Multi-bioregulator stacks: Often combined by organ system in protocols. forum
- Less is clearer: Solo runs make personal n=1 easier to interpret than five-compound blasts. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Generally mild claims: Vendor literature often claims good tolerability — independent long-term data limited. forum
- Allergy / unknown impurities: Gray-market risk. forum
- Injection site (if injected): Redness, itch, lumps, bruise — technique and product quality matter. forum
- Unknowns: Long-term safety for gray-market preparations is often poorly characterized. forum
- Stack noise: Sides logged on multi-agent stacks cannot be blamed cleanly on one compound. forum
- Seek care red flags: Severe allergic reaction, chest pain, neuro changes, or uncontrolled BP/glucose need real medical care — not forum advice. forum
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.